Currently, lung cancer targeted drugs for different lung cancer mutation loci mainly include the following: 1. tyrosine kinase inhibitors for epidermal growth factor (EGFR): they are small molecule inhibitors, such as erlotinib, kamagra, afatinib, oseltinib and other drugs; 2. targeted drugs for ALK gene translocation: such as crizotinib, cretinib and erlotinib; 3. targeted drugs for ROS gene Targeted drugs for ROS gene translocation; such as crizotinib, cretinoin, etc. 4, drugs for BRAF mutation, such as dalafenib and trametinib, etc. Due to the introduction of the above targeted drugs, the survival rate of advanced lung cancer has advanced from no more than 10 months to 40-50 months.